Investors on the quest for market-beating returns often employ the strategy of stock picking. Making informed choices in stocks can greatly amplify your wealth.
Janux Therapeutics Inc (NASDAQ: JANX) closed the day trading at $37.09 up 1.98% from the previous closing price of $36.37. In other words, the price has increased by $1.98 from its previous closing price. On the day, 0.58 million shares were traded.
Ratios:
For a better understanding of JANX, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 38.80 and its Current Ratio is at 38.80. In the meantime, Its Debt-to-Equity ratio is 0.04 whereas as Long-Term Debt/Eq ratio is at 0.03.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, H.C. Wainwright on December 03, 2024, Reiterated its Buy rating but revised its target price to $70 from $63 previously.
On December 03, 2024, BTIG Research reiterated its Buy rating and also lowered its target price recommendation from $82 to $100.
On November 22, 2024, Leerink Partners started tracking the stock assigning a Outperform rating and target price of $79.Leerink Partners initiated its Outperform rating on November 22, 2024, with a $79 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Feb 03 ’25 when Meyer Andrew Hollman sold 3,334 shares for $42.29 per share. The transaction valued at 140,999 led to the insider holds 82,139 shares of the business.
ANDREW MEYER bought 3,334 shares of JANX for $144,962 on Feb 03 ’25. On Jan 07 ’25, another insider, Campbell David Alan, who serves as the President and CEO of the company, sold 5,000 shares for $60.00 each. As a result, the insider received 300,004 and left with 293,054 shares of the company.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 164.27 while its Price-to-Book (P/B) ratio in mrq is 2.96.
Stock Price History:
Over the past 52 weeks, JANX has reached a high of $71.71, while it has fallen to a 52-week low of $8.28. The 50-Day Moving Average of the stock is -25.02%, while the 200-Day Moving Average is calculated to be -21.63%.
Shares Statistics:
A total of 52.34M shares are outstanding, with a floating share count of 48.09M. Insiders hold about 16.80% of the company’s shares, while institutions hold 108.86% stake in the company.
Earnings Estimates
The current assessment of Janux Therapeutics Inc (JANX) involves the perspectives of 9.0 analysts closely monitoring its market dynamics.The consensus estimate for the next quarter is -$0.47, with high estimates of -$0.33 and low estimates of -$0.73.
Analysts are recommending an EPS of between -$0.76 and -$1.61 for the fiscal current year, implying an average EPS of -$1.3. EPS for the following year is -$2.22, with 9.0 analysts recommending between -$1.38 and -$3.73.
Revenue Estimates
A total of 11 analysts have provided revenue estimates for JANX’s current fiscal year. The highest revenue estimate was $13M, while the lowest revenue estimate was $10.59M, resulting in an average revenue estimate of $11.03M. In the same quarter a year ago, actual revenue was $8.08M
